Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Management of von Hippel-Lindau disease-associated CNS lesions Wind JJ; Lonser RRExpert Rev Neurother 2011[Oct]; 11 (10): 1433-41Patients with von Hippel-Lindau disease (VHL) often harbor significant disease burden within the CNS, specifically craniospinal-axis hemangioblastomas and endolymphatic sac tumors (ELSTs). The majority (60-80%) of patients with VHL harbor hemangioblastomas, and 10-15% will develop ELSTs. Advances in the understanding of the natural history and outcomes associated with the surgical management of VHL-associated tumors have led to improved management of patients with VHL. Optimizing indications for surgical intervention and refining of surgical techniques for these lesions can reduce patient morbidity associated with the management of this syndrome. In this article, we review the various aspects of perioperative management of patients with VHL, surgical indications and general operative principles for the management of hemangioblastomas and ELSTs, and outcomes associated with the surgical treatment of these tumors.|Central Nervous System Neoplasms/complications/diagnosis/pathology/*therapy[MESH]|Endolymphatic Sac/pathology/physiopathology/surgery[MESH]|Hemangioblastoma/complications/genetics/pathology/surgery[MESH]|Humans[MESH]|Treatment Outcome[MESH]|Von Hippel-Lindau Tumor Suppressor Protein/*physiology[MESH]|von Hippel-Lindau Disease/complications/diagnosis/*pathology/*therapy[MESH] |